Globe Newswire
Luxembourg, 04 November 2026, 09:30 CET
With reference to Article 19(3) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), ArcelorMittal announces that a notification of share transactions by Lumen Investments S.à r.l., an entity forming part of the Significant Shareholder structure, is available in the Luxembourg Stock Exchange's electronic database OAM on www.bourse.lu and on... (continue reading...)
SHENZHEN, CHINA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Rxilient Medical received approval from the Health Sciences Authority of Singapore (HSA) on 3 November 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product” or “Lumirix®”) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of... (continue reading...)
Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) today announces that it has revised its consolidated financial forecast for the year ending 31 December 2026, previously announced on 13 February 2026, as set out below.
1. Revision of forecast of full-year consolidated financial results for fiscal 2026(January 1, 2026 to December 31, 2026)
Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) today announces that it has revised its consolidated financial forecast for the year ending 31 December 2026, previously announced on 13 February 2026, as set out below.
1. Revision of forecast of full-year consolidated financial results for fiscal 2026(January 1, 2026 to December 31, 2026)
- Nxera to receive US$100 million upfront and be eligible for up to US$1.37 billion in development and commercial milestone payments, plus tiered royalties.
- NXE0033744, an investigational oral EP4 receptor agonist discovered using Nxera’s NxWave™ drug discovery platform, is a potential first-in-class candidate for inflammatory bowel disease.
Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that... (continue reading...)
More Globe Newswire
View Older Stories-
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
-
NBPE - Holding(s) in Company
-
PRE ANNOUNCEMENT OF CERTIFICATE AUCTION TENDER
-
UCLOUDLINK GROUP INC. to Report Third Quarter 2026 Financial Results on November 11, 2026
-
Danske Bank A/S, transactions by persons discharging managerial responsibilities
-
Nokia Global Network Traffic Report forecasts AI will drive nearly half of global traffic in 2035
-
CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF GBP 750,000,000 Senior Non-Preferred Callable Fixed Rate Resettable Notes issued on November 29, 2022 (ISIN: FR001400E920)*
-
London Parade Set to Roll-in 2027
-
MathCo Appoints Vijay Raj as Member of MathCo Advisory Board
-
Sampo plc cancels repurchased shares
-
Wolters Kluwer 2026 Nine-Month Trading Update
-
NBPE Announces Transaction in Own Shares
-
Transaction in Own Shares
-
GEVORKYAN Successfully Refinances EUR 30 Million in Bonds. Investor Demand Exceeded the Issue Size.
-
Novo raises full-year outlook on continued GLP-1 momentum, with third-quarter adjusted operating profit increasing 27% at CER to DKK 31,720 million
-
Pandora delivers 6% organic growth in Q3 - Guidance narrowed towards upper end
-
Sampo Group’s results for January–September 2026
-
Q1-Q3 Interim Report 2026 - Nykredit Realkredit Group
-
Trading update for 1 January – 30 September 2026
-
STMicroelectronics reveals advanced microcontrollers for real-time power control in AI datacenters and robotics
-
Vopak reports strong YTD performance, raises FY 2026 outlook
-
Start of Day Message
-
STM32 Summit 2026: STMicroelectronics announces its unified MCU platform, addressing technology convergence across industrial, automotive and physical AI applications
-
Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder
-
SIKA DRIVES GROWTH IN TUNNELING AND MINING THROUGH INDUSTRYOS PARTNERSHIP
-
dsm-firmenich reports Q3 2026 trading update
-
Solvay third quarter 2026 results
-
Onderzoek ABN AMRO: 7 op de 10 Nederlanders zeggen nepwebshops nauwelijks nog te herkennen
-
INTERIM REPORT OF MARIMEKKO, 1 Jan–30 Sept 2026: Marimekko’s net sales and operating profit increased in the third quarter due to the excellent development of international sales
-
From Real-World Applications to Scale: AiMOGA Robotics Advances Its Commercialization Strategy
-
CheckYourCar.org Launches New Site to Help Drivers Compare Car Insurance Rates Without Spam Calls
-
ALJJ Outlines Digital Asset Services and Platform Development Priorities
-
Mowi ASA (OSE: MOWI): Quarterly dividend
-
Lerøy Seafood Group ASA: Invitation to presentation of third quarter 2026 results
-
Record-high profits, revenues and volumes for Mowi
-
Rekordhøye resultater, omsetning og volumer for Mowi
-
Music Unites Hearts at Charity Concert for Children in Qingdao
-
Next Point LLC Advises Specialized Therapy Billing Company on Strategic Transaction Amid Shifting RCM Market
-
The Ensign Group, Inc. Notice of December 7, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
-
Duolingo, Inc. Notice of December 7, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
-
The Chemours Company Securities Fraud Class Action Result of Overstatement of Refrigerant Aftermarket Demand and 18% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
-
Everest Group, Ltd. Notice of December 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
-
Gildan Activewear Inc. Securities Fraud Class Action Result of Alleged Channel Stuffing and 18.7% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
-
Millrose Properties, Inc. Securities Fraud Class Action Result of Undisclosed Rental Home Business and 8.5% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
-
Honeywell Aerospace, Inc. Notice of November 23, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
-
CGTN: Global Mayors Dialogue reaffirms China's commitment to openness
-
CGTN: Global Mayors Dialogue reaffirms China's commitment to openness
-
iCAUR V25 Continues to Attract Overseas Attention Following Its Global Debut, with Design and Customization in the Spotlight
-
Helm Expands into Australia with Presence in Sydney
-
SSE Develops Sustainability Framework That Adapts to Different Small-Business Operations
